Treatment of Local Regional Disease
Nonseminomatous germ cell tumor is an extraordinary tumor in terms of demonstrating the impact of regional lymphadenectomy on survival. Over the years many series have shown that node-positive (pathologic stage II) patients can be cured with local measures in excess of 50% of cases. There are a variety of anatomical considerations that make testicular lymphatic drainage predictable. These relate to features of anatomic descent of the gonad and its associated lymphatics. A number of topographic studies have supported the regional deposition of metastatic disease, and we have a good understanding of this. More importantly, there are biologic considerations that probably lend to the opportunity for cure of testis cancer patients with surgery alone. Many patients will have teratomatous elements which have somewhat lower metastatic potential. What is fascinating, however, is that even undifferentiated germ cell tumors, such as embryonal cancer, are often cured with lymphadenectomy alone. Data recently presented in a multiinstitutional cooperative study show that a control group treated with node dissection alone had more than half of the patients as long-term survivors without relapse .
KeywordsGerm Cell Tumor Testicular Cancer Testis Cancer Nonseminomatous Germ Cell Retroperitoneal Lymph Node Dissection
Unable to display preview. Download preview PDF.
- 2.Donohue JP et al. (1988) Preservation of ejaculation following nerve-sparing retroperitoneal lymphadenectomy. J Urol 139:206A (abstr no 176)Google Scholar
- 11.Donohue JP, Rowland RG, Bihrle R (1988) Transabdominal retroperitoneal lymph node dissection. In: Skinner DG, Leiskovsky G (eds) Diagnosis and management of genitourinary cancer. Saunders, Philadelphia, pp 802–816Google Scholar
- 13.Donohue JP, Foster RS, Rowland RG et al. (1991) Nerve-sparing retroperitoneal lymphadenectomy. J Urol (Submitted)Google Scholar
- 16.Hoskins P, Dilly S, Easton D (1986) Prognostic factors in stage I nonseminomatous germ, cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 4:1031–1036Google Scholar